Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog

Karoly Szepeshazi, Andrew V Schally, Attila Nagy, Gabor Halmos

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives: Targeting anticancer agents to receptors for peptide hormones such as bombesin/gastrin-releasing peptide (GRP) on tumor cells increases the efficacy and lowers the toxicity of cancer therapy. We studied the expression of bombesin/GRP receptors in 6 experimental pancreatic cancers and evaluated tumor inhibition in vivo produced by targeted chemotherapy with the cytotoxic bombesin analog AN-215. Methods: Nude mice with xenografts of Pane-1, CFPAC-1, Capan-1, Capan-2, MiaPaCa-2, and SW-1990 human ductal pancreatic cancers, as well as hamsters with nitrosamine-induced pancreatic cancers, were treated with AN-215 or its cytotoxic radical 2-pyrrolinodoxorubicin (AN-201) for 7 to 12 weeks. Tumor growth reduction and survival were analyzed, and cell proliferation rate and apoptosis were examined by histologic methods. Bombesin/GRP receptors on the tumors were studied by ligand-binding assays and their mRNA expression was studied by reverse transcriptase-polymerase chain reaction. Results: All tumors expressed mRNA for subtype 1 bombesin/GRP receptor, but MiaPaCa-2, and in one experiment, SW-1990 tumors did not show binding sites for bombesin. AN-215 powerfully inhibited the growth of all pancreatic cancers that expressed functional receptors for bombesin/GRP. AN-201 was less effective on most tumors and somewhat more toxic than AN-215. Conclusions: Bombesin/GRP receptors are expressed on most ductal pancreatic carcinoma cell lines and can be used for targeted chemotherapy with the cytotoxic bombesin analog AN-215.

Original languageEnglish
Pages (from-to)275-282
Number of pages8
JournalPancreas
Volume31
Issue number3
DOIs
StatePublished - Oct 1 2005
Externally publishedYes

Fingerprint

Bombesin
Pancreatic Neoplasms
Cricetinae
Bombesin Receptors
Growth
Neoplasms
Pancreatic Ductal Carcinoma
Gastrin-Releasing Peptide
Drug Therapy
Nitrosamines
Messenger RNA
Peptide Receptors
Poisons
Reverse Transcriptase Polymerase Chain Reaction
Heterografts
Nude Mice
Antineoplastic Agents
Binding Sites
Cell Proliferation
AN 215

Keywords

  • Bombesin/gastrin-releasing peptide receptor
  • Cytotoxic bombesin analog
  • Pancreatic carcinoma
  • Targeted cancer therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Endocrinology

Cite this

Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. / Szepeshazi, Karoly; Schally, Andrew V; Nagy, Attila; Halmos, Gabor.

In: Pancreas, Vol. 31, No. 3, 01.10.2005, p. 275-282.

Research output: Contribution to journalArticle

@article{8f958c5fddaa4bdb81e251344f896f48,
title = "Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog",
abstract = "Objectives: Targeting anticancer agents to receptors for peptide hormones such as bombesin/gastrin-releasing peptide (GRP) on tumor cells increases the efficacy and lowers the toxicity of cancer therapy. We studied the expression of bombesin/GRP receptors in 6 experimental pancreatic cancers and evaluated tumor inhibition in vivo produced by targeted chemotherapy with the cytotoxic bombesin analog AN-215. Methods: Nude mice with xenografts of Pane-1, CFPAC-1, Capan-1, Capan-2, MiaPaCa-2, and SW-1990 human ductal pancreatic cancers, as well as hamsters with nitrosamine-induced pancreatic cancers, were treated with AN-215 or its cytotoxic radical 2-pyrrolinodoxorubicin (AN-201) for 7 to 12 weeks. Tumor growth reduction and survival were analyzed, and cell proliferation rate and apoptosis were examined by histologic methods. Bombesin/GRP receptors on the tumors were studied by ligand-binding assays and their mRNA expression was studied by reverse transcriptase-polymerase chain reaction. Results: All tumors expressed mRNA for subtype 1 bombesin/GRP receptor, but MiaPaCa-2, and in one experiment, SW-1990 tumors did not show binding sites for bombesin. AN-215 powerfully inhibited the growth of all pancreatic cancers that expressed functional receptors for bombesin/GRP. AN-201 was less effective on most tumors and somewhat more toxic than AN-215. Conclusions: Bombesin/GRP receptors are expressed on most ductal pancreatic carcinoma cell lines and can be used for targeted chemotherapy with the cytotoxic bombesin analog AN-215.",
keywords = "Bombesin/gastrin-releasing peptide receptor, Cytotoxic bombesin analog, Pancreatic carcinoma, Targeted cancer therapy",
author = "Karoly Szepeshazi and Schally, {Andrew V} and Attila Nagy and Gabor Halmos",
year = "2005",
month = "10",
day = "1",
doi = "10.1097/01.mpa.0000175892.97036.a7",
language = "English",
volume = "31",
pages = "275--282",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog

AU - Szepeshazi, Karoly

AU - Schally, Andrew V

AU - Nagy, Attila

AU - Halmos, Gabor

PY - 2005/10/1

Y1 - 2005/10/1

N2 - Objectives: Targeting anticancer agents to receptors for peptide hormones such as bombesin/gastrin-releasing peptide (GRP) on tumor cells increases the efficacy and lowers the toxicity of cancer therapy. We studied the expression of bombesin/GRP receptors in 6 experimental pancreatic cancers and evaluated tumor inhibition in vivo produced by targeted chemotherapy with the cytotoxic bombesin analog AN-215. Methods: Nude mice with xenografts of Pane-1, CFPAC-1, Capan-1, Capan-2, MiaPaCa-2, and SW-1990 human ductal pancreatic cancers, as well as hamsters with nitrosamine-induced pancreatic cancers, were treated with AN-215 or its cytotoxic radical 2-pyrrolinodoxorubicin (AN-201) for 7 to 12 weeks. Tumor growth reduction and survival were analyzed, and cell proliferation rate and apoptosis were examined by histologic methods. Bombesin/GRP receptors on the tumors were studied by ligand-binding assays and their mRNA expression was studied by reverse transcriptase-polymerase chain reaction. Results: All tumors expressed mRNA for subtype 1 bombesin/GRP receptor, but MiaPaCa-2, and in one experiment, SW-1990 tumors did not show binding sites for bombesin. AN-215 powerfully inhibited the growth of all pancreatic cancers that expressed functional receptors for bombesin/GRP. AN-201 was less effective on most tumors and somewhat more toxic than AN-215. Conclusions: Bombesin/GRP receptors are expressed on most ductal pancreatic carcinoma cell lines and can be used for targeted chemotherapy with the cytotoxic bombesin analog AN-215.

AB - Objectives: Targeting anticancer agents to receptors for peptide hormones such as bombesin/gastrin-releasing peptide (GRP) on tumor cells increases the efficacy and lowers the toxicity of cancer therapy. We studied the expression of bombesin/GRP receptors in 6 experimental pancreatic cancers and evaluated tumor inhibition in vivo produced by targeted chemotherapy with the cytotoxic bombesin analog AN-215. Methods: Nude mice with xenografts of Pane-1, CFPAC-1, Capan-1, Capan-2, MiaPaCa-2, and SW-1990 human ductal pancreatic cancers, as well as hamsters with nitrosamine-induced pancreatic cancers, were treated with AN-215 or its cytotoxic radical 2-pyrrolinodoxorubicin (AN-201) for 7 to 12 weeks. Tumor growth reduction and survival were analyzed, and cell proliferation rate and apoptosis were examined by histologic methods. Bombesin/GRP receptors on the tumors were studied by ligand-binding assays and their mRNA expression was studied by reverse transcriptase-polymerase chain reaction. Results: All tumors expressed mRNA for subtype 1 bombesin/GRP receptor, but MiaPaCa-2, and in one experiment, SW-1990 tumors did not show binding sites for bombesin. AN-215 powerfully inhibited the growth of all pancreatic cancers that expressed functional receptors for bombesin/GRP. AN-201 was less effective on most tumors and somewhat more toxic than AN-215. Conclusions: Bombesin/GRP receptors are expressed on most ductal pancreatic carcinoma cell lines and can be used for targeted chemotherapy with the cytotoxic bombesin analog AN-215.

KW - Bombesin/gastrin-releasing peptide receptor

KW - Cytotoxic bombesin analog

KW - Pancreatic carcinoma

KW - Targeted cancer therapy

UR - http://www.scopus.com/inward/record.url?scp=25844439526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25844439526&partnerID=8YFLogxK

U2 - 10.1097/01.mpa.0000175892.97036.a7

DO - 10.1097/01.mpa.0000175892.97036.a7

M3 - Article

C2 - 16163060

AN - SCOPUS:25844439526

VL - 31

SP - 275

EP - 282

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 3

ER -